MXPA03011391A - 2,5-diarilpirazinas, 2,5-diarilpiridinas y 2,5-diarilpirimidinas como moudladores de receptor crf1. - Google Patents

2,5-diarilpirazinas, 2,5-diarilpiridinas y 2,5-diarilpirimidinas como moudladores de receptor crf1.

Info

Publication number
MXPA03011391A
MXPA03011391A MXPA03011391A MXPA03011391A MXPA03011391A MX PA03011391 A MXPA03011391 A MX PA03011391A MX PA03011391 A MXPA03011391 A MX PA03011391A MX PA03011391 A MXPA03011391 A MX PA03011391A MX PA03011391 A MXPA03011391 A MX PA03011391A
Authority
MX
Mexico
Prior art keywords
alkyl
phenyl
amino
mono
compound
Prior art date
Application number
MXPA03011391A
Other languages
English (en)
Spanish (es)
Inventor
Ge Ping
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of MXPA03011391A publication Critical patent/MXPA03011391A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA03011391A 2001-06-12 2002-05-22 2,5-diarilpirazinas, 2,5-diarilpiridinas y 2,5-diarilpirimidinas como moudladores de receptor crf1. MXPA03011391A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29748301P 2001-06-12 2001-06-12
PCT/US2002/016518 WO2002100838A1 (en) 2001-06-12 2002-05-22 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators

Publications (1)

Publication Number Publication Date
MXPA03011391A true MXPA03011391A (es) 2004-07-01

Family

ID=23146501

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011391A MXPA03011391A (es) 2001-06-12 2002-05-22 2,5-diarilpirazinas, 2,5-diarilpiridinas y 2,5-diarilpirimidinas como moudladores de receptor crf1.

Country Status (16)

Country Link
US (2) US6887875B2 (https=)
EP (1) EP1399428A1 (https=)
JP (1) JP2005500286A (https=)
AP (1) AP2003002924A0 (https=)
BG (1) BG108427A (https=)
CA (1) CA2450262A1 (https=)
EC (1) ECSP034898A (https=)
HR (1) HRP20031096A2 (https=)
HU (1) HUP0400179A3 (https=)
IL (1) IL159058A0 (https=)
IS (1) IS7060A (https=)
MX (1) MXPA03011391A (https=)
PL (1) PL367476A1 (https=)
RU (1) RU2003136151A (https=)
TN (1) TNSN03133A1 (https=)
WO (1) WO2002100838A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4368001A (en) * 2000-03-16 2001-09-24 Neurogen Corporation 5-substituted arylpyrimidines
CA2480497A1 (en) * 2002-04-26 2003-11-06 Pharmacia & Upjohn Company Substituted pyrazine derivatives
ATE325115T1 (de) 2002-08-19 2006-06-15 Glaxo Group Ltd Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
WO2004046136A1 (en) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators
JP2007512275A (ja) 2003-11-24 2007-05-17 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾリルおよびイミダゾリルピリミジン
EP1768972A1 (de) * 2004-07-14 2007-04-04 Basf Aktiengesellschaft 2-substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
CN101258142A (zh) * 2005-08-02 2008-09-03 莱西肯医药有限公司 作为蛋白激酶抑制剂的2-氨基芳基吡啶
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
CN102812014B (zh) * 2009-10-30 2016-01-20 多美恩医疗公司 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
WO2014179786A1 (en) * 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
CN105254576A (zh) * 2014-02-26 2016-01-20 中国科学院长春应用化学研究所 一种谷氨酸二酮哌嗪的制备方法
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP2022074173A (ja) * 2019-03-18 2022-05-18 住友化学株式会社 ２，５－ジクロロピラジンの製造方法
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用
CN113429354A (zh) * 2021-07-22 2021-09-24 广东嘉博制药有限公司 一种盐酸甲氧明聚合物杂质及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463813A (fr) * 1964-02-26 1966-07-22 Ciba Geigy Nouvelles amino-phénylcétones et procédé pour leur préparation
US3660404A (en) * 1969-02-24 1972-05-02 Du Pont U.v.-absorbing ortho-hydroxyphenyl substituted bipyrimidyls
DE2064380C3 (de) * 1970-12-30 1981-01-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Gemisch
JPS625970A (ja) 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
DE68926635T2 (de) * 1988-04-25 1997-01-02 Dainippon Ink & Chemicals 2,5-Disubstituierte Pyrazin-Derivate, Pyrimidin-Derivate und sie enthaltende Flüssigkristalle
JPH02209873A (ja) * 1989-02-08 1990-08-21 Dainippon Ink & Chem Inc 光学活性２，５―ジ置換ピリミジン誘導体
JP2770385B2 (ja) * 1989-03-16 1998-07-02 セイコーエプソン株式会社 ピリミジン誘導体
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
JPH0948760A (ja) * 1995-08-03 1997-02-18 Dainippon Ink & Chem Inc ピリミジン化合物
JP4044175B2 (ja) * 1996-07-26 2008-02-06 株式会社半導体エネルギー研究所 光学活性化合物及び該化合物を含有する反強誘電性液晶組成物
US6686486B1 (en) * 1997-05-07 2004-02-03 Padma Marwah Process for effecting allylic oxidation
SE9702651D0 (sv) * 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
NZ506101A (en) * 1998-01-28 2003-06-30 Shionogi & Co Tricyclic immunosupressant, anti-allergic and IgE production suppressant compounds
CO5210940A1 (es) * 1999-05-04 2002-10-30 Novartis Ag Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen
CN1231473C (zh) * 2000-02-16 2005-12-14 神经能质公司 取代的芳基吡嗪

Also Published As

Publication number Publication date
HUP0400179A3 (en) 2004-10-28
US20050176721A1 (en) 2005-08-11
PL367476A1 (en) 2005-02-21
US20030119844A1 (en) 2003-06-26
HUP0400179A2 (hu) 2004-08-30
JP2005500286A (ja) 2005-01-06
BG108427A (bg) 2005-01-31
ECSP034898A (es) 2004-01-28
IS7060A (is) 2003-11-28
HRP20031096A2 (en) 2005-08-31
TNSN03133A1 (en) 2005-12-23
WO2002100838A1 (en) 2002-12-19
CA2450262A1 (en) 2002-12-19
AP2003002924A0 (en) 2003-12-31
US6887875B2 (en) 2005-05-03
IL159058A0 (en) 2004-05-12
RU2003136151A (ru) 2005-05-20
EP1399428A1 (en) 2004-03-24

Similar Documents

Publication Publication Date Title
MXPA03011391A (es) 2,5-diarilpirazinas, 2,5-diarilpiridinas y 2,5-diarilpirimidinas como moudladores de receptor crf1.
ES2247070T3 (es) Arilpirazinas sustituidas.
US20080107608A1 (en) 5-Substituted-2-Arylpyridines
RS61002B1 (sr) Formulacija rnk za imunoterapiju
US20080015196A1 (en) Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
US20050234051A1 (en) 5-Substituted 2-aryl-4 pyrimidinones
AU4368001A (en) 5-substituted arylpyrimidines
JP2006509729A (ja) Ｃｒｆ受容体モジュレータとしての５−置換−２−アリールピラジン類
AU2002310117A1 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as CRF1 receptor modulators
AU2002314809A1 (en) 5-substituted-2-arylpyridines as CRF1 modulators
ZA200206103B (en) Substituted arylpyrazines.